Overview

MannKind Corporation (Nasdaq:MNKD) is a biopharmaceutical company that focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Our lead investigational product candidate, AFREZZA® , is an ultra rapid-acting insulin. AFREZZA is in late stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia.

Featured Links


Receive E-mail AlertsE-mail Alert Icon
Alerts are e-mailed to you whenever certain new company information is posted to this site.
Sign-up Now!
MNKD (Common Stock)
ExchangeNASDAQ GM (US Dollar)
Price$9.56
Change (%) Stock is Down 0.21 (2.15%)
Volume5,665,200
Data as of 07/23/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore Press Releases
DateTitle 
06/27/14MannKind Corporation Announces FDA Approval of AFREZZA(R); A Novel, Rapid-Acting Inhaled Insulin for the Treatment of Diabetes
VALENCIA, Calif., June 27, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today announced that the U.S. Food & Drug Administration (FDA) has approved AFREZZA® (insulin human) Inhalation Powder to improve glycemic control in adult patients with diabetes mellitus. "Approval of AFREZZA is an important milestone for MannKind, as today's FDA action validates the years of clinical research and commitment that powered the development of this unique therapy," said Alfred Mann, Chief... 
Printer Friendly Version
05/27/14MannKind to Present at Upcoming Conferences
VALENCIA, Calif., May 27, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), focused on discovering, developing and commercializing treatments for diabetes, announced today that it will present at upcoming conferences. Jefferies 2014 Global Healthcare Conference on Monday, June 2, 2014 at 2:30 pm (ET) in New York, New York.   Goldman Sachs 35th Annual Global Healthcare Conference on Thursday, June 12, 2014 at 11:20 am (PT) at the Terranea Resort in Rancho Palos Verdes, Califo... 
Printer Friendly Version
05/12/14MannKind Corporation Reports 2014 First Quarter Financial Results
Conference Call to Begin Today at 5:00 PM ET VALENCIA, Calif., May 12, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today reported financial results for the first quarter ended March 31, 2014. For the first quarter of 2014, total operating expenses were $41.4 million, compared to $36.4 million for the first quarter of 2013, an increase of $5.0 million. Research and development (R&D) expenses were $26.2 million for the first quarter of 2014, compared to $26.4 million for t... 
Printer Friendly Version
05/07/14MannKind to Present at Bank of America Merrill Lynch 2014 Health Care Conference
VALENCIA, Calif., May 7, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), focused on discovering, developing and commercializing treatments for diabetes, announced today that it will present at the Bank of America Merrill Lynch 2014 Health Care Conference on Wednesday, May 14, 2014 at 8:40 am Pacific Time at the Encore at the Wynn Hotel in Las Vegas, Nevada. Interested parties can access a link to the live webcast of the presentations from the News & Events section of the Compan... 
Printer Friendly Version
Quotes delayed at least 15 minutes. Market data provided by Interactive Data.

Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.



Print Page Print | E-mail Page E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts | IR Contacts IR Contacts | Financial Tear Sheet Tear Sheet